+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026

  • ID: 4968354
  • Report
  • February 2020
  • Region: Global
  • 510 Pages
  • Kuick Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now
Since Commercial Launch in 2015, the Global Bispecific Antibody Market Has Witnessed Growth of 118% CAGR Till 2019

FEATURED COMPANIES

  • Ablynx
  • Amgen
  • Eli Lilly
  • Genentech
  • Jounce Therapeutics
  • Neovii Biotech
  • MORE

"Global Bispecific Antibody Market Opportunity, Drug Sales & Clinical Trials Insight 2026" Report Highlights:

  • Global Bispecific Antibody Market Opportunity:  > US$ 10 Billion
  • Global Bispecific Antibody Market Growth:  118% CAGR (2015 -2019)
  • Global Bispecific Antibody Market Growth In 2019:  280% (> US$ 1.5 Billion)
  • Global Bispecific Antibody Pipeline:  333 Drug
  • Commercially Available Bispecific Antibodies: 2 (Blincyto & Hemlibra)
  • Hemlibra Sales & Market Share 2019: > US$ 1.4 Billion & > 80%

“Global Bispecific Antibody Market Opportunity, Drug Sales  & Clinical Trials Insight 2026” provides comprehensive insight on clinical and non-clinical factors that are driving the global bispecific antibodies market and its impact on the global pharmaceutical market landscape. The report has been prepared in a view to deeply profile the current market trends along with the sales insight on two (Blincyto & Hemlibra) commercially available bispecific antibodies with their regional level revenue, market share and the clinical profile.

Since Commercial Launch In 2015, The Global Bispecific Antibody Market Has Witnessed Growth of 118% CAGR Till 2019

The availability of the bispecific antibodies in the market and the revenue generated by the drugs in short span of four years (since commercialization in 2015) clearly depicts the current dominant trends followed by its characterization as a next generation of antibody therapy. The number of the investigational agents under preclinical and clinical trials all around the globe adds as a major key component for the establishment of the antibody therapy as a one stop treatment for all the disease.

Pharmaceutical companies involved in the development of these promising bispecific antibodies molecules strongly believe that their products are superior to first generation nonspecific antibody products. No doubt they are adamant to their viewpoint that bispecific antibodies will be more potent against disease targets, which includes combating more than one aspect of the disease simultaneously, better and cheaper production with least side effects. The molecules are also said to have the potential of dealing with multiple disease with a single agent making them more important.
 
Structural Diversity Among The Antibodies Are Opening A Wide Plethora For The Novel Bispecific Antibody Agents, And Thus Providing A Great Opportunity For Establishing A Superior Market In The Future.

Bispecific antibodies are not only being developed for the oncological use but also the non oncological which includes rejection of organ transplants, inflammatory and autoimmune disorders, cardiovascular disease, infectious diseases, allergies and ophthalmic problems making their usage area wide enough to make ample of monetary gains in the near future. Their vitality if approved can also make them a great tool in the diagnostics tests detect and monitor infectious agents like HIV, the cause of AIDS, or the influenza virus causing pandemic flu and for identifying diseases released by biological weapons such as smallpox and anthrax.

In addition, monoclonal antibodies have also helped in checks for salmonella and bacteria that cause food poisoning. The global opportunity value of the bispecific antibody market is estimated to be approximately US$ 10 billion per year, which is expected to be achieved in next five-year timeframe.

Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Ablynx
  • Amgen
  • Eli Lilly
  • Genentech
  • Jounce Therapeutics
  • Neovii Biotech
  • MORE

1. Introduction to Bispecific Monoclonal Antibody
1.1 Overview of Monoclonal Antibody
1.2 Overview of Bispecific Monoclonal Antibody
1.3 Advantage of Bispecific Antibodies upon Monospecific Monoclonal Antibodies

2. The Engineering & Development of Bispecific Antibodies
2.1 Bispecific Antibodies Similar to IgG
2.1.1 Quadroma (Hybrid Hydromas) Approach
2.1.2 “Knobs Into Holes” Approach
2.1.3 CrossMab Approach
2.1.4 Dual-Variable-Domain Immunoglobulin Approach
2.2 Small Bispecific Antibodies
2.2.1 Bispecific Diabodies
2.2.2 Bispecific T-Cell Engager Antibodies (BiTEs)

3. Mechanism Of Action Of Bispecific Antibody
3.1 Trifunctional Antibody: Catumaxomab (Removab®)
3.2 Blinatumomab

4. Applications of Bispecific Antibodies in Diagnostic & Treatment
4.1 BsMAb for Diagnosis of Bacterial & Viral Infectious Diseases
4.2 BsMAb for Cancer Diagnostic
4.3 BsAbs Blocking Signaling Pathways
4.4 BsAbs Targeting Tumor Angiogenesis
4.5 Specific Delivery of Effector Compounds to Targets
4.6 Bispecific Antibodies & Gene Therapy

5. Global Bispecific Antibody Market Outlook
5.1 Current Market Scenario
5.2 Availability of Bispecific Antibodies
5.2.1 Catumaxomab (Removab)
5.2.2 Blinatumomab
5.2.3 Emicizumab
5.2.4 Duligotumab
5.2.5 SAR 156597

6. Approved Bispecific Antibody Dosage & Price Analysis
6.1 Blincyto
6.2 Hemlibra

7. Approved Bispecific Antibody Sales Analysis
7.1 Blincyto
7.2 Hemlibra

8. Global Bispecific Antibodies Clinical Pipeline Overview
8.1 By Phase
8.2 By Country/Region
8.3 By Company
8.4 By Indication
8.5 Orphan Designated Bispecific Antibodies

9. Global Bispecific Antibodies Clinical Pipeline By Company, Indication & Phase
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-II/III
9.7 Phase-III

10. Marketed Bispecific Antibodies Clinical Insight
10.1 Blinatumomab - Amgen
10.2 Emicizumab - Chugai Pharmaceutical

11. Global Bispecific Antibody Market Dynamics
11.1 Favorable Market Parameters
11.2 Commercialization Challenges

12. Global Bispecific Antibody Market Future Prospects

13. Competitive Landscape
13.1 Ablynx
13.2 Adimab
13.3 Affimed Therapeutics
13.4 Amgen
13.5 AstraZeneca (MedImmune)
13.6 Chugai Pharmaceutical
13.7 Eli Lilly
13.8 EMD Serono
13.9 Emergent BioSolutions
13.10 Genentech
13.11 Genmab
13.12 Immunomedics
13.13 Jounce Therapeutics
13.14 MacroGenics
13.15 Merus
13.16 Neovii Biotech
13.17 NovImmune SA
13.18 OncoMed Pharmaceuticals
13.19 Pieris
13.20 Regeneron Pharmaceuticals
13.21 Roche
13.22 Sanofi

List of Figures

Figure 1-1: Advantages of Bispecific Antibodies
Figure 2-1: Types of Approaches to Form IgG like Bispecific Antibodies
Figure 2-2: Method of Formation of Hybrid Hybridoma
Figure 2-3: Limitations of Hybrid Hybridoma
Figure 2-4: Steps involved in “Knobs into Holes” Approach
Figure 2-5: Three different CrossMabs are Obtained by Three Different Modifications
Figure 2-6: Method for formation of Dual-Variable-Domain Immunoglobulin
Figure 2-7: Advantages of Dual Variable Domain Immunoglobulin approach
Figure 2-8: Types of Bispecific Antibodies
Figure 3-1: Mechanism of Action of Bispecific Monoclonal Antibody
Figure 3-2: Mechanism of Action of Catumaxomab
Figure 3-3: Mechanism of Action of Blinatumomab
Figure 4-1: Applications of Bispecific Antibodies
Figure 5-1: Global - Bispecific Antibody Market Size (US$ Million), 2015 - 2019
Figure 5-2: US v/s ROW - Bispecific Antibody Market Share (%), 2018
Figure 5-3: US v/s ROW - Bispecific Antibody Market Share (%), 2019
Figure 5-4: Global - Bispecific Antibody Market Size (US$ Million) by Products (Blincyto & Hemlibra), 2018 & 2019
Figure 5-5: Global - Bispecific Antibody Market Share(%) by Products (Blincyto & Hemlibra), 2018
Figure 5-6: Global - Bispecific Antibody Market Share(%) by Products (Blincyto & Hemlibra), 2019
Figure 5-7: Global - Bispecific Antibody Quarterly Sales (US$ Million), by Products (Blincyto & Hemlibra), 2019
Figure 6-1: Blincyto - Recommended Number of Induction & Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL, December’2019
Figure 6-2: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days), December’2019
Figure 6-3: Blincyto - Cost of Single Cycle & Full Treatment Cost of MRD+ B-Cell Precursor ALL (US$), December’2019
Figure 6-4: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL, December’2019
Figure 6-5: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks), December’2019
Figure 6-6: Blincyto - Cost of 1st & 2nd Induction Cycle for Treatment of Relapsed B-Cell Precursor ALL (US$), December’2019
Figure 6-7: Blincyto - Cost of Different Treatment Phases & Full Treatment Cost for Relapsed B-Cell Precursor ALL (US$), December’2019
Figure 6-8: Hemlibra - Cost for Single Unit of 30mcg & 150mcg Subcutaneous Injection (US$), December’2019
Figure 6-9: Hemlibra - Recommended Loading & Maintenance Dose for Treatment of Hemophilia (mg/Kg/Week), December’2019
Figure 6-10: Hemlibra - Average Monthly & Annual Cost for Treatment of Hemophilia A (US$), December’2019
Figure 7-1: Blincyto - Sales Value (US$ Million), 2015 - 2019
Figure 7-2: US - Blincyto Sales Value (US$ Million), 2016 - 2019
Figure 7-3: Global ( Ex USA) - Blincyto Sales Value (US$ Million), 2016 - 2019
Figure 7-4: Blincyto - Quarterly Sales Value (US$ Million), 2018
Figure 7-5: Blincyto - Quarterly Sales Value (US$ Million), 2019
Figure 7-6: Blincyto - US v/s Rest of World Share in Sales Value (%), 2018
Figure 7-7: Blincyto - US v/s Rest of World Share in Sales Value (%), 2019
Figure 7-8: Hemlibra - Sales Value by Countries (US$ Million), 2019
Figure 7-9: Hemlibra - Sales Value by Countries (US$ Million), 2018
Figure 7-10: Hemlibra - Sales Value Share by Countries (%), 2018
Figure 7-11: Global - Hemlibra Quarterly Sales Value (US$ Million), 2018
Figure 7-12: Global - Hemlibra Half Yearly Sales Value (US$ Million), 2018 & 2019
Figure 7-13: Hemlibra - Half Year Sales Value by Countries (US$ Million), 2018 & 2019
Figure 7-14: Hemlibra - Quarterly Sales Value (US$ Million), 2019
Figure 7-15: Hemlibra - 9 Months Sales Value by Countries (US$ Million), 2019
Figure 7-16: Hemlibra - 9 Month Sales Value Share by countries (%), 2019
Figure 8-1: Global - Bispecific Antibodies Clinical Pipeline by Phase (%), 2020 till 2026
Figure 8-2: Global - Bispecific Antibodies Clinical Pipeline by Phase (Numbers), 2020 till 2026
Figure 8-3: Global - Bispecific Antibodies in Clinical Pipeline by Country (Numbers), 2020 till 2026
Figure 8-4: Global - Bispecific Antibodies in Clinical Pipeline by Company (Numbers), 2020 till 2026
Figure 8-5: Global - Bispecific Antibodies in Clinical Pipeline by Indication (Numbers), 2020 till 2026
Figure 8-6: Global - Bispecific Antibodies in Clinical Pipeline by Orphan Status (Numbers), 2020 till 2026
Figure 11-1: Favorable Market Parameters Global Bispecific Antibody Market
Figure 11-2: Commercialization Challenges for Bispecific Antibody
Figure 12-1: Global - Bispecific Antibody Market Opportunity Assessment (US$ Billion), 2020 – 2026
Figure 13-1: Ablynx - Clinical Pipeline
Figure 13-2: Affimed Therapeutics - Clinical Pipeline
Figure 13-3: Amgen - Clinical Pipeline
Figure 13-4: EMD Serono - Clinical Pipeline
Figure 13-5: Emergent Bioscience - Clinical Pipeline
Figure 13-6: Genmab - Clinical Pipeline
Figure 13-7: Jounce Therapeutics - Clinical Pipeline
Figure 13-8: MacroGenics - Clinical Pipeline
Figure 13-9: Merus - Clinical Pipeline
Figure 13-10: Novimmune - Clinical Pipeline
Figure 13-11: OncoMed - Clinical Pipeline
Figure 13-12: Pieris Pharmaceuticals - Clinical Pipeline
Figure 13-13: Roche - Clinical Pipeline

List of Tables

Table 2-1: List of Bispecific Antibodies Formed by Hybrid Hybridoma Method
Table 2-2: List of Bispecific Antibodies Formed by DART
Table 2-3: List of Bispecific Antibodies Formed by BiTE Method
Table 2-4: List of Other BiTEs
Table 4-1: Bispecific Antibodies Targeting Cancer

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Ablynx
  • Adimab
  • Affimed Therapeutics
  • Amgen
  • AstraZeneca (MedImmune)
  • Chugai Pharmaceutical
  • Eli Lilly
  • EMD Serono
  • Emergent BioSolutions
  • Genentech
  • Genmab
  • Immunomedics
  • Jounce Therapeutics
  • MacroGenics
  • Merus
  • Neovii Biotech
  • Neovii Biotech
  • OncoMed Pharmaceuticals
  • Pieris
  • Regeneron Pharmaceuticals
  • Roche
  • Sanofi
Note: Product cover images may vary from those shown
Adroll
adroll